Diel Patrick
Deutsche Sporthochschule Köln, Institute of Morphology and Tumor Research, Carl-Diem-Weg 6, 50927 Cologne, Germany.
Toxicol Lett. 2002 Feb 28;127(1-3):217-24. doi: 10.1016/s0378-4274(01)00503-3.
Estrogens exert profound effects on growth, differentiation, and function of many reproductive tissues. They also affect other tissues, including bone, liver, cardiovascular system, and brain. In the last few years it has been demonstrated that several synthetic estrogens can act in a tissue-specific manner. The first example of such a selective estrogen receptor modulator (SERM) was tamoxifen, for which an estrogen agonist-like activity in the endometrium and bone was seen to occur simultaneously with an estrogen antagonist activity in the breast. The mechanisms by which the same compound can exert tissue-specific agonist and antagonist actions are still being investigated. Important aspects include the interaction of the ligand with the two estrogen receptor subtypes and the interaction of these ligand-receptor complexes with effectors, which include different DNA response elements and important coregulator proteins. In addition to well-documented effects on gene transcription, there is evidence that estrogen receptors and other estrogen binding proteins are involved in some rapid, non-genomic effects of estrogens in target cells. For these reasons it is important to point out that a toxicological evaluation of endocrine modulators should include an analysis of potential SERM-like properties.
雌激素对许多生殖组织的生长、分化和功能具有深远影响。它们还会影响其他组织,包括骨骼、肝脏、心血管系统和大脑。在过去几年中,已证明几种合成雌激素可呈现组织特异性作用方式。此类选择性雌激素受体调节剂(SERM)的首个实例是他莫昔芬,其在子宫内膜和骨骼中表现出类似雌激素激动剂的活性,同时在乳腺中呈现雌激素拮抗剂活性。同一化合物发挥组织特异性激动剂和拮抗剂作用的机制仍在研究之中。重要方面包括配体与两种雌激素受体亚型的相互作用,以及这些配体 - 受体复合物与效应器的相互作用,效应器包括不同的DNA反应元件和重要的共调节蛋白。除了对基因转录有充分记录的影响外,有证据表明雌激素受体和其他雌激素结合蛋白参与了雌激素在靶细胞中的一些快速非基因组效应。出于这些原因,必须指出,内分泌调节剂的毒理学评估应包括对潜在SERM样特性的分析。